Regulus Therapeutics have a $US600million deal with GSK for up to 4 potential candidates using microRNA.
http://finance.yahoo.com/news/Regulus-Therapeutics-and-prnews-99230071.html?x=0&.v=1
BLT and ddRNAi need some industry support soon.
The lack of any news on progress is not helping the share price, that's for sure.